دورية أكاديمية
أعرض في EDS

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.

التفاصيل البيبلوغرافية
العنوان: Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.
المؤلفون: Dong Y; Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou., Li Q; Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou., Miao Q; Department of Medical Oncology, Quzhou People's Hospital, Zhongloudi, Quzhou, Zhejiang, China., Li D; Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou.
المصدر: Medicine [Medicine (Baltimore)] 2021 Jun 25; Vol. 100 (25), pp. e26450.
نوع المنشور: Case Reports; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Brain Neoplasms/*therapy , Carcinoma, Non-Small-Cell Lung/*therapy , Erlotinib Hydrochloride/*therapeutic use , Lung Neoplasms/*therapy , Neoplasm Recurrence, Local/*therapy , Salvage Therapy/*methods, Biopsy ; Brain/diagnostic imaging ; Brain/pathology ; Brain Neoplasms/genetics ; Brain Neoplasms/mortality ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; Chemoradiotherapy/methods ; Drug Resistance, Neoplasm ; Drug Substitution ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Erlotinib Hydrochloride/pharmacology ; Gefitinib/pharmacology ; Gefitinib/therapeutic use ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/pathology ; Progression-Free Survival ; Radiotherapy, Intensity-Modulated ; Response Evaluation Criteria in Solid Tumors
مستخلص: Rationale: The guidelines recommended gefitinib as a first-line targeted treatment for stage IV non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment for patients without T790m mutation. The case is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib.
Patient Concerns: We described a 55-year-old man with good performance status (PS).
Diagnoses: He was histopathologically diagnosed stage IV lung adenocarcinoma with EGFR mutations in November 2018.
Interventions: He was administrated with gefitinib daily (250 mg) for activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions,19del), and combined with platinum-based dual-drug chemotherapy. During the target treatments, the optimal efficacy evaluation was partial remission (PR) with a 12-month progression-free survival (PFS) time. Later, the intracranial progression of the patient rendered the treatment change to erlotinib.
Outcomes: It is surprising that the tumor lesion in brain as well as lung relieved obviously. His progression-free survival (PFS)was nearly 11 months, and the overall survival (OS)was>36 months up to now. The adverse events were tolerable.
Lessions: This case manifests that re-biopsy of advanced or recurrent NSCLC is beneficial to make a better therapeutic regimen, and erlotinib can be used as a salvage treatment after gefitinib failure.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. doi: 10.3322/caac.21492. PubMed PMID: 30207593. (PMID: 10.3322/caac.21492.)
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–39. Epub 2015/09/29. doi: 10.1056/NEJMoa1507643. PubMed PMID: 26412456; PubMed Central PMCID: PMCPMC5705936. (PMID: 10.1056/NEJMoa1507643.)
Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–84. Epub 2015/03/22. doi: 10.1016/S1470-2045(15)70076-8. PubMed PMID: 25795410. (PMID: 10.1016/S1470-2045(15)70076-8.)
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8. doi: 10.1056/NEJMoa0909530. PubMed PMID: 20573926. (PMID: 10.1056/NEJMoa0909530.)
Zhou C, Wu Y, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–42. doi: 10.1016/s1470-2045(11)70184-x. PubMed PMID: 21783417. (PMID: 10.1016/s1470-2045(11)70184-x.)
Jackman D, Pao W, Riely G, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357–60. doi: 10.1200/jco.2009.24.7049. PubMed PMID: 19949011. (PMID: 10.1200/jco.2009.24.7049.)
Tan C, Gilligan D, Pacey SJTLO. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 2015;16:e447–59. doi: 10.1016/s1470-2045(15)00246-6. PubMed PMID: 26370354. (PMID: 10.1016/s1470-2045(15)00246-6.)
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92. Epub 2005/02/25. doi: 10.1056/NEJMoa044238. PubMed PMID: 15728811. (PMID: 10.1056/NEJMoa044238.)
Wu S, Shih JJMc. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 2018;17:38doi: 10.1186/s12943-018-0777-1. PubMed PMID: 29455650. (PMID: 10.1186/s12943-018-0777-1.)
Takezawa K, Pirazzoli V, Arcila M, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790 M mutation. Cancer Discov 2012;2:922–33. doi: 10.1158/2159-8290.Cd-12-0108. PubMed PMID: 22956644. (PMID: 10.1158/2159-8290.Cd-12-0108.)
Engelman J, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–43. doi: 10.1126/science.1141478. PubMed PMID: 17463250. (PMID: 10.1126/science.1141478.)
Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281–9. Epub 2009/07/28. doi: 10.3816/CLC.2009.n.039. PubMed PMID: 19632948; PubMed Central PMCID: PMCPMC2758558. (PMID: 10.3816/CLC.2009.n.039.)
Khan NA, Mirshahidi S, Mirshahidi HR. A novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib. Case Rep Oncol 2014;7:491–6. Epub 2014/09/10. doi: 10.1159/000365325. PubMed PMID: 25202264; PubMed Central PMCID: PMCPMC4154193. (PMID: 10.1159/000365325.)
Gristina V, Malapelle U, Galvano A, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal. Cancer Treat Rev 2020;85:101994doi: 10.1016/j.ctrv.2020.101994. PubMed PMID: 32113081. (PMID: 10.1016/j.ctrv.2020.101994.)
Oxnard G, Arcila M, Sima C, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790 M mutation. Clin Cancer Res 2011;17:1616–22. doi: 10.1158/1078-0432.Ccr-10-2692. PubMed PMID: 21135146. (PMID: 10.1158/1078-0432.Ccr-10-2692.)
Lee D, Kim S, Suh C, et al. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008;19:2039–42. doi: 10.1093/annonc/mdn423. PubMed PMID: 18644828. (PMID: 10.1093/annonc/mdn423.)
Singh N, Jindal A, Behera DJWjoco. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. World J Clin Oncol 2014;5:858–64. doi: 10.5306/wjco.v5.i5.858. PubMed PMID: 25493223. (PMID: 10.5306/wjco.v5.i5.858.)
Gandara D, Li T, Lara P, et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer 2014;15:01–6. doi: 10.1016/j.cllc.2013.10.001. PubMed PMID: 24176733. (PMID: 10.1016/j.cllc.2013.10.001.)
Yang J, Chen H, Yan H, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013;79:33–9. doi: 10.1016/j.lungcan.2012.09.016. PubMed PMID: 23079155. (PMID: 10.1016/j.lungcan.2012.09.016.)
Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 2020;38:115–23. doi: 10.1200/jco.19.01488. PubMed PMID: 31682542. (PMID: 10.1200/jco.19.01488.)
Mok T, Kim S, Wu Y, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol 2017;35:4027–34. doi: 10.1200/jco.2017.73.9250. PubMed PMID: 28968167. (PMID: 10.1200/jco.2017.73.9250.)
Sacher A, Paweletz C, Dahlberg S, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2016;2:1014–22. doi: 10.1001/jamaoncol.2016.0173. PubMed PMID: 27055085. (PMID: 10.1001/jamaoncol.2016.0173.)
Oxnard G, Thress K, Alden R, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 2016;34:3375–82. doi: 10.1200/jco.2016.66.7162. PubMed PMID: 27354477. (PMID: 10.1200/jco.2016.66.7162.)
Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018;29:i10–9. Epub 2018/02/21. doi: 10.1093/annonc/mdx703. PubMed PMID: 29462254; PubMed Central PMCID: PMCPMC6454547. (PMID: 10.1093/annonc/mdx703.)
Jiang T, Ren S, Zhou CJLc. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer 2015;90:128–34. doi: 10.1016/j.lungcan.2015.09.013. PubMed PMID: 26415994. (PMID: 10.1016/j.lungcan.2015.09.013.)
Song T, Yu W, Wu S-X. Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI? Asian Pac J Cancer Prev 2014;15:205–13. doi: 10.7314/apjcp.2014.15.1.205. PubMed PMID: 24528028. (PMID: 10.7314/apjcp.2014.15.1.205.)
Jackman D, Holmes A, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517–20. doi: 10.1200/jco.2006.06.6126. PubMed PMID: 16983123. (PMID: 10.1200/jco.2006.06.6126.)
Cheng Y, Ma L, Liu Y, et al. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors. Lung Cancer 2020;145:63–70. doi: 10.1016/j.lungcan.2020.04.004. PubMed PMID: 32408134. (PMID: 10.1016/j.lungcan.2020.04.004.)
Hou H, Qin K, Liang Y, et al. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res 2019;11:5665–75. doi: 10.2147/cmar.S201513. PubMed PMID: 31417310. (PMID: 10.2147/cmar.S201513.)
Canale M, Petracci E, Delmonte A, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res 2017;23:2195–202. Epub 2016/11/01. doi: 10.1158/1078-0432.CCR-16-0966. PubMed PMID: 27780855. (PMID: 10.1158/1078-0432.CCR-16-0966.)
Lee J, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol 2017;35:3065–74. doi: 10.1200/jco.2016.71.9096. PubMed PMID: 28498782. (PMID: 10.1200/jco.2016.71.9096.)
Haven B, Heilig E, Donham C, et al. Registered report: a chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Elife 2016;05doi: 10.7554/eLife.09462. PubMed PMID: 26905833. (PMID: 10.7554/eLife.09462.)
Becker A, Crombag L, Heideman D, et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011;47:2603–6. doi: 10.1016/j.ejca.2011.06.046. PubMed PMID: 21784628. (PMID: 10.1016/j.ejca.2011.06.046.)
Sequist L, Waltman B, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26, doi: 10.1126/scitranslmed.3002003. PubMed PMID: 21430269. (PMID: 10.1126/scitranslmed.3002003.)
Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150–5. Epub 2007/09/06. doi: 10.1158/1078-0432.CCR-07-0560. PubMed PMID: 17785570. (PMID: 10.1158/1078-0432.CCR-07-0560.)
Chaft J, Oxnard G, Sima C, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298–303. doi: 10.1158/1078-0432.Ccr-11-1468. PubMed PMID: 21856766. (PMID: 10.1158/1078-0432.Ccr-11-1468.)
Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol 2018;13:1383–92. Epub 2018/06/01. doi: 10.1016/j.jtho.2018.05.019. PubMed PMID: 29852232. (PMID: 10.1016/j.jtho.2018.05.019.)
Lo P, Dahlberg S, Nishino M, et al. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer 2015;121:2570–7. doi: 10.1002/cncr.29397. PubMed PMID: 25876525. (PMID: 10.1002/cncr.29397.)
Patel P, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol (R Coll Radiol) 2019;31:824–33. doi: 10.1016/j.clon.2019.05.015. PubMed PMID: 31182289. (PMID: 10.1016/j.clon.2019.05.015.)
Kumar A, Petri E, Halmos B, et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26:1742–51. doi: 10.1200/jco.2007.12.1178. PubMed PMID: 18375904. (PMID: 10.1200/jco.2007.12.1178.)
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32. Epub 2005/07/15. doi: 10.1056/NEJMoa050753. PubMed PMID: 16014882. (PMID: 10.1056/NEJMoa050753.)
Blackhall F, Ranson M, Thatcher F. Where next for gefitinib in patients with lung cancer? Lancet Oncol 2006;7:499–507. doi: 10.1016/s1470-2045(06)70725-2. PubMed PMID: 16750500. (PMID: 10.1016/s1470-2045(06)70725-2.)
Honeywell RJ, Kathmann I, Giovannetti E, et al. Epithelial transfer of the tyrosine kinase inhibitors erlotinib, gefitinib, afatinib, crizotinib, sorafenib, sunitinib, and dasatinib: implications for clinical resistance. Cancers (Basel) 2020;12: Epub 2020/11/14. doi: 10.3390/cancers12113322. PubMed PMID: 33182766; PubMed Central PMCID: PMCPMC7696666. (PMID: 10.3390/cancers12113322.)
Horiike A, Yamamoto N, Tanaka H, et al. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. Anticancer Res 2014;34:1975–81. PubMed PMID: 24692734.
Wu S, Chiang C, Liu C, et al. EGFR An observational study of acquired T790M-dependent resistance to EGFR-TKI treatment in lung adenocarcinoma patients in Taiwan. Front Oncol 2020;10:1481doi: 10.3389/fonc.2020.01481. PubMed PMID: 33014788. (PMID: 10.3389/fonc.2020.01481.)
Lin Y, Chen J, Liao W, et al. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790 M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer 2019;144:2887–96. doi: 10.1002/ijc.32025. PubMed PMID: 30485437. (PMID: 10.1002/ijc.32025.)
Flippot R, Biondani P, Auclin E, et al. Activity of EGFR tyrosine kinase inhibitors in NSCLC with refractory leptomeningeal metastases. J Thorac Oncol 2019;14:1400–7. doi: 10.1016/j.jtho.2019.05.007. PubMed PMID: 31108248. (PMID: 10.1016/j.jtho.2019.05.007.)
Cho K, Keam B, Kim T, Lee SH, Kim DW, Heo DS. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean J Intern Med 2015;30:891–8. doi: 10.3904/kjim.2015.30.6.891. PubMed PMID: 26552465. (PMID: 10.3904/kjim.2015.30.6.891.)
Hata A, Katakami N, Yoshioka H, et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer 2011;74:268–73. doi: 10.1016/j.lungcan.2011.03.010. PubMed PMID: 21529987. (PMID: 10.1016/j.lungcan.2011.03.010.)
Kwon B, Park J, Kim W, et al. Predictive factors for switched EGFR-TKI retreatment in patients with EGFR-mutant non-small cell lung cancer. Tuberc Repair Dis (Seoul) 2017;80:187–93. doi: 10.4046/trd.2017.80.2.187. PubMed PMID: 28416959. (PMID: 10.4046/trd.2017.80.2.187.)
المشرفين على المادة: DA87705X9K (Erlotinib Hydrochloride)
EC 2.7.10.1 (EGFR protein, human)
EC 2.7.10.1 (ErbB Receptors)
S65743JHBS (Gefitinib)
تواريخ الأحداث: Date Created: 20210623 Date Completed: 20210629 Latest Revision: 20230103
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8238270
DOI: 10.1097/MD.0000000000026450
PMID: 34160440
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000026450